Related Experiment Video
Updated: Jan 17, 2026

Polar Histogram Visualization of Acute Stress Disorder Scale Scores for Comprehensive Clinical Assessment
Published on: December 6, 2024
Influence of Preexisting Psychotic and Bipolar Disorders on the Outcomes of Acutely Hospitalized Patients With
Mojtaba Sharafkhah1, Nozhan Alimi2, Zeinab Haghighi Fini2
1Graduate Program in Neuroscience, Schulich School of Medicine and Dentistry, Western University, London, ON.
Insights
Patients with psychotic and bipolar disorders (PsBPs) experienced worse COVID-19 outcomes, including higher intensive care unit admission and mortality rates. Early detection and interventions are crucial for this vulnerable group.
Area of Science:
- Psychiatry
- Infectious Diseases
- Public Health
Background:
- Preexisting conditions significantly impact COVID-19 outcomes.
- Psychotic and bipolar disorders (PsBPs) represent a vulnerable patient population.
- Understanding the specific impact of PsBPs on COVID-19 is critical for targeted care.
Purpose of the Study:
- To assess the impact of preexisting psychotic and bipolar disorders (PsBPs) on COVID-19 outcomes.
- To compare COVID-19 severity and mortality rates between patients with and without PsBPs.
Main Methods:
- Retrospective cohort study of 7,370 hospitalized COVID-19 patients.
- Patients categorized into PsBP group and no psychiatric disorders (NPD) group.
- Analysis of demographic data, clinical features, ICU admission, and in-hospital mortality.
Main Results:
- 12.2% of COVID-19 patients had PsBPs.
- PsBP group showed significantly higher ICU admission (44.5% vs. 21.8%) and mortality rates (39.2% vs. 23.8%).
- Shorter time intervals to ICU admission and death were observed in the PsBP group.
Conclusions:
- COVID-19 patients with PsBPs exhibit poorer outcomes, including increased severity, ICU admission, and mortality.
- Findings underscore the need for early identification and specialized interventions for individuals with PsBPs.
- Proactive management strategies are essential to mitigate adverse COVID-19 outcomes in this population.
Objective:
COVID-19 outcomes are often worse among patients with preexisting conditions. The authors assessed the impact of preexisting psychotic and bipolar disorders (PsBPs) on COVID-19 outcomes.
Methods:
A retrospective cohort study was conducted with COVID-19 patients admitted to three medical centers between April 20, 2020, and October 20, 2023. Patients were grouped into individuals with PsBPs (i.e., schizophrenia, other psychotic disorders, and bipolar disorders) and those with no psychiatric disorders (NPDs), defined as individuals without preexisting conditions such as nonpsychotic depression or anxiety. Data on demographic characteristics, clinical features, and COVID-19 severity were collected. The primary outcome was COVID-19 in-hospital mortality rate, and the secondary outcome was the association of PsBPs with COVID-19 severity.
Results:
Among 7,370 hospitalized COVID-19 patients (43.7% female; mean age=42.7 years), 12.2% had a PsBP. Patients with PsBPs had higher intensive care unit (ICU) admission rates (44.5% vs. 21.8%, p=0.003) and mortality rates (39.2% vs. 23.8%, p=0.045). Time intervals to ICU admission (7.3 vs. 8.2 days, p=0.001) and in-hospital death (8.0 vs. 12.2 days, p=0.001) were significantly shorter in the PsBP group, compared with the NPD group.
Conclusions:
COVID-19 patients with PsBPs had worse outcomes, including higher ICU admission and mortality rates, and greater disease severity. These findings highlight the importance of early detection and tailored interventions for this vulnerable population.
Related Concept Videos
Bipolar Disorder
Psychosis: Goals of Pharmacotherapy
Psychological and Sociocultural Causes of Schizophrenia
Psychosis and Antipsychotic Drugs: Overview
Mania and Antimanic Drugs: Overview
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...

